Trial Profile
Bendamustine + Obinutuzumab Induction Chemoimmunotherapy With Risk-adapted Obinutuzumab Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Obinutuzumab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 23 Jan 2024 Status changed from active, no longer recruiting to discontinued.
- 18 Jul 2023 Planned primary completion date changed from 15 May 2024 to 31 Jul 2023.
- 18 Jul 2023 Status changed from recruiting to active, no longer recruiting.